Dr. Kapoor, a biotechnology patent attorney, is reviewing 180 gene sequences for novelty. She classifies 1/3 as novel, 1/4 as obvious, and the rest as common. Of the novel ones, 25% are deemed patentable after legal review. How many gene sequences are patentable?
["Dr. Kapoor Reviews 180 Gene Sequences: Patent Potential Revealed", "In a high-stakes review of biotechnology innovations, Dr. Kapoor, a leading patent attorney specializing in life sciences, is analyzing 180 gene sequences to determine their patentability. This meticulous evaluation involves leveraging deep expertise in biotech IP law, genomics, and regulatory standards.", "Breaking Down the Gene Sequence Classification", "Dr. Kapoor categorizes the gene sequences as follows:\n- Novel sequences: 1/3 of 180 → 60 sequences\n- Obvious sequences: 1/4 of 180 → 45 sequences\n- Common (non-patentable) sequences: The remainder → 180 – 60 – 45 = 75 sequences", "Of the 60 novel sequences identified, not all qualify for patent protection. Under current U.S. and international patent law, especially guidelines from the USPTO and EPO, only portions of a novel gene—such as engineered variants, specific applications, or novel uses—may be patentable.", "Dr. Kapoor conducts a legal review of each novel sequence and finds that 25% of them meet the criteria for patentability.", "Calculating Patentable Sequences", "25% of 60 novel sequences:\n[\n0.25 \ imes 60 = 15\n]", "Thus, 15 gene sequences are deemed patentable after legal scrutiny.", "Why Patentability Matters in Biotechnology", "Biotech patent law is highly nuanced, balancing innovation incentives with public access to scientific knowledge. Dr. Kapoor’s work ensures that only truly novel and non-obvious gene sequences receive patent protection—protecting inventors while advancing ethical and legal standards in genetic research.", "With 180 sequences assessed, only 15 emerge as strong candidates for intellectual property rights, underscoring the rigorous but vital role of specialized patent attorneys like Dr. Kapoor in shaping biotech innovation.", "Addibly, precision in classification and legal review minimizes patent disputes and accelerates translational research."]
